Structural biology of SARS-CoV-2 and implications for therapeutic development
H Yang, Z Rao - Nature Reviews Microbiology, 2021 - nature.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
[HTML][HTML] Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach
The sudden emergence of severe respiratory disease, caused by a novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently become a public health …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently become a public health …
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
A Narayanan, M Narwal, SA Majowicz… - Communications …, 2022 - nature.com
SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug
development. In this study, we present an antiviral screening strategy involving a novel in …
development. In this study, we present an antiviral screening strategy involving a novel in …
SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …
protease inhibitor specifically developed against the SARS-CoV-2 protease 3CLpro that has …
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
There is an urgent need for antiviral agents that treat severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs …
coronavirus 2 (SARS-CoV-2) infection. We screened a library of 1900 clinically safe drugs …
[HTML][HTML] Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
Structural insights into SARS-CoV-2 proteins
The unprecedented scale of the ongoing COVID-19 pandemic has catalyzed an intense
effort of the global scientific community to unravel different aspects of the disease in a short …
effort of the global scientific community to unravel different aspects of the disease in a short …
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started
to circulate among humans around December 2019, and it is now widespread as a global …
to circulate among humans around December 2019, and it is now widespread as a global …
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiological agent
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
responsible for the global COVID-19 (coronavirus disease 2019) outbreak. The main …
Structural basis of potential inhibitors targeting SARS-CoV-2 main protease
The Coronavirus disease-19 (COVID-19) pandemic is still devastating the world causing
significant social, economic, and political chaos. Corresponding to the absence of globally …
significant social, economic, and political chaos. Corresponding to the absence of globally …